Axsome Therapeutics (AXSM) Misses Q4 EPS by 28c

Axsome Therapeutics (NASDAQ: AXSM) reported Q4 EPS of ($1.41), $0.28 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $24.37 million versus the consensus estimate of $21.76 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• AutoZone (AZO) Tops Q4 EPS by $1.76, Misses on Revenue
• UBS Reiterates Buy Rating on Option Care Health (OPCH) Following Check-in Call Ahead of Quiet Period